Investigating how LAG3 interacts with antibodies and ligands to improve cancer treatment
Official title: Structure-function studies of LAG3 interactions with antibodies and cellular ligands
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11104541 · Data updated 2026-11-12
This study is looking at how a protein called LAG3 affects the way our immune cells fight cancer, with the goal of finding better treatments that use LAG3 to boost the immune response against tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $549,962 |
| NIH project number | 1R01CA299899-01 |
| Project ID | NIH-11104541 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that may benefit from LAG3-targeting therapies, particularly those with metastatic melanoma.
✕Less likely to help
Patients with non-cancerous conditions or those whose cancers are not responsive to immunotherapy may not benefit from this research.
What this research studies
This research focuses on understanding the role of Lymphocyte-Activation Gene 3 (LAG3) in regulating T cell activation, which is crucial for effective cancer immunotherapy. The team will explore how different antibodies and cellular ligands interact with LAG3, aiming to clarify the mechanisms behind its immunosuppressive functions. By studying these interactions, the research seeks to identify optimal strategies for enhancing the effectiveness of LAG3-targeting therapies in cancer treatment. This work builds on previous findings that have led to FDA-approved therapies and aims to fill critical gaps in our understanding of LAG3's molecular biology.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that enhance T cell activation and improve patient outcomes.
How similar studies have gone: Previous research has successfully targeted LAG3 in clinical settings, indicating a promising avenue for further exploration in cancer immunotherapy.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Luca, Vincent Christopher — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Luca, Vincent Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.